Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
Rhea-AI Summary
NeOnc Technologies (NASDAQ: NTHI) received an updated coverage report highlighting stronger clinical and regulatory positioning in 2Q26. Lead asset NEO100 achieved its Phase 2a primary endpoint, with six‑month PFS of 48.9% by RANO 2.0 versus a 20% benchmark (p=0.0047), median OS of 26.09 months, and no major toxicities. The company plans to seek an FDA Type B meeting to discuss a potential registrational program. NEO212 advanced through Phase 2 CMC clearance and FDA feedback indicating a possible accelerated approval pathway. R&D expenses rose to $2.6M from $0.7M year over year, while management expands development into meningioma and pediatric brain tumors, noting that funding remains important as activity increases.
Positive
- NEO100 Phase 2a PFS-6 48.9% vs 20% benchmark (p=0.0047)
- NEO100 median OS 26.09 months with no major toxicities reported
- NEO100 moving toward potential registrational trial after positive Phase 2a readout
- NEO212 gains Phase 2 CMC clearance and potential accelerated approval feedback
- Pipeline expansion with NEO100 in meningioma and pediatric brain tumors
Negative
- Confirmation of NEO100 results still requires a randomized study
- R&D expenses increased to $2.6M vs $0.7M year over year
- Company notes funding remains important as development activity expands
News Explained
This August 13 coverage update adds no stated financing or ownership terms; as of March 31, NeOnc had
Sources and calculations
- Stonegate Capital Partners coverage update (2026-08-13)
- NeOnc first-quarter fundamentals (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $138,601 / ($6,991,773 / 90) = [object Object]
Market reaction after Phase 2a clinical data: NTHI +31.78% in the Aug 14 session
In the Aug 14 session, NTHI gained 31.78%, reflecting a significant positive market reaction. Argus tracked a peak move of +30.7% during that session. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 27.7x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | NEO100 clinical data | Positive | -21.1% | Phase 2a data met the primary endpoint with positive survival and tolerability results. |
| Aug 12 | NEO100 clinical data | Positive | -21.1% | Topline Phase 2a results reported positive progression-free survival and overall survival. |
| Aug 10 | Phase 2a data preview | Neutral | +0.0% | The company scheduled release of topline Phase 2a results for August 12. |
| Aug 10 | 2Q26 earnings report | Negative | +0.0% | Higher R&D spending and net loss were reported alongside clinical progress. |
| Aug 10 | Investor conference call | Neutral | +0.0% | Management scheduled a webcast to discuss Phase 2a results and regulatory next steps. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical announcements on August 12 were followed by negative 24-hour reactions, indicating repeated divergence between clinical news sentiment and observed price response.
Key Terms
kaplan-meier estimation technical
type b fda meeting regulatory
cmc clearance regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). 2Q26 meaningfully improves the clinical setup for NTHI, with NEO100 delivering a positive Phase 2a readout and NEO212 gaining regulatory clarity. NEO100 met its primary endpoint with six-month PFS of
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
NEO100's Phase 2a readout materially strengthens the lead program, with PFS-6 of
48.9% versus the20% benchmark and median OS of 26.09 months. The favorable tolerability profile and lack of major toxicities further support the potential for chronic, patient-friendly treatment and move NEO100 toward a registrational-stage opportunity.FDA alignment is now the key near-term catalyst, with NeOnc planning a Type B meeting to determine NEO100's registrational trial design, endpoints and potential approval pathway. NEO212 also gained regulatory momentum through Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway.
The investment case is broadening beyond a single trial or asset, with NEO100 extending into meningioma and pediatric brain tumors while NEO212 provides a differentiated second clinical program. This platform breadth increases longer-term optionality, although funding remains important as development activity expands.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309582